Bacteriemia e infecciones endovasculares por grampositivos: nuevas opciones terapéuticas

Martin, 2003, The epidemiology of sepsis in the United States from 1979 through 2000, N Engl J Med, 348, 1546, 10.1056/NEJMoa022139 Esteban, 2007, Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward, Crit Care Med, 35, 1284, 10.1097/01.CCM.0000260960.94300.DE Siegman-Igra, 2002, Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia, Clin Infect Dis, 34, 1431, 10.1086/339809 Wisplinghoff, 2004, Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study, Clin Infect Dis, 39, 309, 10.1086/421946 National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470-85. Friedman, 2002, Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community—acquired infections, Ann Intern Med, 137, 791, 10.7326/0003-4819-137-10-200211190-00007 Moreillon, 2004, Infective endocarditis, Lancet, 363, 139, 10.1016/S0140-6736(03)15266-X Mylonakis, 2001, Infective endocarditis in adults, N Engl J Med, 345, 1318, 10.1056/NEJMra010082 Fowler, 2005, Staphylococcus aureus endocarditis: a consequence of medical progress, JAMA, 293, 3012, 10.1001/jama.293.24.3012 Horstkotte, 2004, Guidelines on prevention, diagnosis and treatment of infective endocarditis. Executive summary, Rev Esp Cardiol, 57, 952, 10.1157/13066456 Baddour, 2005, Circulation, 111, e394, 10.1161/CIRCULATIONAHA.105.165564 Cisneros-Herreros, 2007, Guía para el diagnóstico y tratamiento del paceinte con bacteriemia. Guías de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica, Enferm Infecc Microbiol Clin, 25, 111, 10.1016/S0213-005X(07)74242-8 Mermel, 2001, Guidelines for the management of intravascular catheter-related infections, Infect Control Hosp Epidemiol, 22, 222, 10.1086/501893 Gavaldá, 2007, Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone, Ann Intern Med, 146, 574, 10.7326/0003-4819-146-8-200704170-00008 Knoll, 2007, Infective endocarditis due to penicillin-resistant viridans group streptococci, Clin Infect Dis, 44, 1585, 10.1086/518174 Jeffres, 2006, Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices, Chest, 130, 947, 10.1378/chest.130.4.947 Sakoulas, 2004, Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia, J Clin Microbiol, 42, 2398, 10.1128/JCM.42.6.2398-2402.2004 Mohr, 2007, Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus, Clin Infect Dis, 44, 1536, 10.1086/518451 Moellering, 2003, Linezolid: the first oxazolidinone antimicrobial, Ann Intern Med, 138, 135, 10.7326/0003-4819-138-2-200301210-00015 Jones, 2006, Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations, J Antimicrob Chemother, 57, 279, 10.1093/jac/dki437 Birmingham, 2003, Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program, Clin Infect Dis, 36, 159, 10.1086/345744 Dobbs, 2006, Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center, J Clin Microbiol, 44, 3368, 10.1128/JCM.00850-06 Kainer MA, Devasia RA, Jones TF, Simmons BP, Melton K, Chow S, et al. Response to emerging infection leading to outbreak of linezolid-resistant enterococci. Emerg Infect Dis [serial on the Internet] [accedido Jul 2007]. Disponible en: http://www.cdc.gov/EID/content/13/7/1024.htm Sánchez-Gómez, 2006, Linezolid-resistant Enterococcus faecalis: first report in Spain, J Chemother, 18, 440, 10.1179/joc.2006.18.4.440 Shorr, 2005, Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies, J Antimicrob Chemother, 56, 923, 10.1093/jac/dki355 Cannon, 2006, The effectiveness and safety of oral linezolid as primary or secondary treatment of bloodstream infections. A retrospective observational analysis, Infect Dis Clin Pract, 14, 221, 10.1097/01.idc.0000226868.52136.24 Dailey, 2001, Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 45, 2304, 10.1128/AAC.45.8.2304-2308.2001 Chiang, 2003, Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 47, 3002, 10.1128/AAC.47.9.3002-3004.2003 Jacqueline, 2005, In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 49, 45, 10.1128/AAC.49.1.45-51.2005 Jacqueline, 2006, In vitro and in vivo assessment of linezolid combined with ertapenem: a highly synergistic combination against methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 50, 2547, 10.1128/AAC.01501-05 Jacqueline, 2002, In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model, Antimicrob Agents Chemother, 46, 3706, 10.1128/AAC.46.12.3706-3711.2002 Del Rio, 2006, ¿Podemos mejorar el pronóstico de la endocarditis estafilocócica?, Enferm Infecc Microbiol Clin, Monogr, 5, 58 Falagas, 2006, Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence, J Antimicrob Chemother, 58, 273, 10.1093/jac/dkl219 Peeters, 2005, Clinical characteristics of linezolid-resistant Staphylococcus aureus infections, Am J Med Sci, 330, 102, 10.1097/00000441-200508000-00007 Tsiodras, 2001, Linezolid resistance in a clinical isolate of Staphylococcus aureus, Lancet, 358, 207, 10.1016/S0140-6736(01)05410-1 Sperber, 2003, Persistent MRSA bacteremia in a patient with low linezolid levels, Clin Infect Dis, 36, 675, 10.1086/367671 Bishop, 2006, Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients, Antimicrob Agents Chemother, 50, 1599, 10.1128/AAC.50.4.1599-1602.2006 Curtin, 2003, Linezolid compared with eperezolid, vancomycin, and gentamicin in an in vitro model of antimicrobial lock therapy for Staphylococcus epidermidis central venous catheter-related biofilm infections, Antimicrob Agents Chemother, 47, 3145, 10.1128/AAC.47.10.3145-3148.2003 Rodríguez-Martínez, 2007, Actividad y permeabilidad de linezolid y vancomicina en biocapas de Staphylococcus epidermidis, Enferm Infecc Microbiol Clin, 25, 425, 10.1157/13108705 Senneville, 2006, Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study, Clin Ther, 28, 1155, 10.1016/j.clinthera.2006.08.001 Falagas, 2007, Linezolid for the treatment of adults with bone and joint infections, Int J Antimicrob Agents, 29, 233, 10.1016/j.ijantimicag.2006.08.030 Soriano, 2007, Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections, Eur J Clin Microbiol Infect Dis, 26, 353, 10.1007/s10096-007-0289-1 Carpenter, 2004, Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens, Clin Infect Dis, 38, 994, 10.1086/383472 Steenbergen, 2005, Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections, J Antimicrob Chemother, 55, 283, 10.1093/jac/dkh546 Hair, 2007, Daptomycin : a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia, Drugs, 67, 1483, 10.2165/00003495-200767100-00008 Cha, 2003, Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations, Diagn Microbiol Infect Dis, 47, 539, 10.1016/S0732-8893(03)00119-6 Thorne, 2002, Daptomycin: a novel lipopeptide antibiotic, Clin Microbiol Newsl, 24, 33, 10.1016/S0196-4399(02)80007-1 Alder, 2003, Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection, Antimicrob Agents Chemother, 47, 3561, 10.1128/AAC.47.11.3561-3566.2003 Smith, 1990, Daptomycin versus vancomycin treatment for Staphylococcus aureus bacteremia in a murine model, Chemotherapy, 36, 428, 10.1159/000238800 Fowler, 2006, Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus, N Engl J Med, 355, 653, 10.1056/NEJMoa053783 Falagas, 2007, Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence, J Antimicrob Chemother, 60, 7, 10.1093/jac/dkm137 Poutsiaka, 2007, Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients, J Infect, 54, 567, 10.1016/j.jinf.2006.11.007 Sakoulas, 2003, Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 47, 1714, 10.1128/AAC.47.5.1714-1718.2003 Voorn, 1994, Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin, Antimicrob Agents Chemother, 38, 487, 10.1128/AAC.38.3.487 Cantoni, 1990, Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination, Antimicrob Agents Chemother, 34, 2348, 10.1128/AAC.34.12.2348 Kaatz, 1990, Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis, Antimicrob Agents Chemother, 34, 2081, 10.1128/AAC.34.11.2081 Kennedy, 1989, Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits, Antimicrob Agents Chemother, 33, 1522, 10.1128/AAC.33.9.1522 Eliopoulos, 1986, In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic, Antimicrob Agents Chemother, 30, 532, 10.1128/AAC.30.4.532 Snydman, 2005, Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and Enterococci by FIC index and timed-kill curves, J Chemother, 17, 614, 10.1179/joc.2005.17.6.614 Cilli, 2006, In vitro activity of daptomycin alone and in combination with various antimicrobials against Gram-positive cocci, J Chemother, 18, 27, 10.1179/joc.2006.18.1.27 Rand, 2004, Synergy of daptomycin with oxacillin and other betalactams against methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 48, 2871, 10.1128/AAC.48.8.2871-2875.2004 Tsuji, 2005, Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations, Antimicrob Agents Chemother, 49, 2735, 10.1128/AAC.49.7.2735-2745.2005 LaPlante, 2004, Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model, Antimicrob Agents Chemother, 48, 4665, 10.1128/AAC.48.12.4665-4672.2004 Torres-Tortosa, 2006, Therapy for methicillin-resistant Staphylococcus aureus, N Engl J Med, 355, 2153, 10.1056/NEJMc062516 Vouillamoz, 2006, Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci, J Antimicrob Chemother, 58, 1208, 10.1093/jac/dkl406 Caron, 1992, Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium, Antimicrob Agents Chemother, 36, 2611, 10.1128/AAC.36.12.2611 Ramos, 1992, Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococci, Antimicrob Agents Chemother, 36, 1864, 10.1128/AAC.36.9.1864 Hindes, 1989, Treatment of experimental endocarditis caused by a beta-lactamaseproducing strain of Enterococcus faecalis with high-level resistance to gentamicin, Antimicrob Agents Chemother, 33, 1019, 10.1128/AAC.33.7.1019 Bush, 1988, Daptomycin (LY146032) treatment of experimental enterococcal endocarditis, Antimicrob Agents Chemother, 32, 877, 10.1128/AAC.32.6.877 Rand, 2004, Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci, J Antimicrob Chemother, 53, 530, 10.1093/jac/dkh104 Rand, 2007, Daptomycin-reversible rifampicin resistance in vancomycin-resistant Enterococcus faecium, J Antimicrob Chemother, 59, 1017, 10.1093/jac/dkm045 Edmiston, 2006, Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices, Am J Surg, 192, 344, 10.1016/j.amjsurg.2006.04.009 Fernández-Hidalgo, 2006, Antibiotic-lock therapy for long-term intravascular catheter-related bacteraemia: results of an open, non-comparative study, J Antimicrob Chemother, 57, 1172, 10.1093/jac/dkl103 Fortún, 2006, Treatment of long-term intravascular catheter-related bacteraemia with antibiotic-lock therapy, J Antimicrob Chemother, 58, 816, 10.1093/jac/dkl318 Laplante, 2007, In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model, Nephrol Dial Transplant, 10.1093/ndt/gfm141 Vaudaux, 2003, Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus, J Antimicrob Chemother, 52, 89, 10.1093/jac/dkg277 Cunha, 2005, Daptomycin cure after cefazolin treatment failure of methicillin-sensitive Staphylococcus aureus (MSSA) tricuspid valve acute bacterial endocarditis from a peripherally inserted central catheter (PICC) line, Heart Lung, 34, 442, 10.1016/j.hrtlng.2005.05.006 Weis, 2007, Daptomycin for eradication of a systemic infection with a methicillin-resistant-Staphylococcus aureus in a biventricular assist device recipient, Ann Thorac Surg, 84, 269, 10.1016/j.athoracsur.2007.02.001 Sader, 2006, The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin, Clin Infect Dis, 43, 798, 10.1086/507109 Hayden, 2005, Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus, J Clin Microbiol, 43, 5285, 10.1128/JCM.43.10.5285-5287.2005 Skiest, 2006, Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin, J Clin Microbiol, 44, 655, 10.1128/JCM.44.2.655-656.2006 Marty, 2006, Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis, J Clin Microbiol, 44, 595, 10.1128/JCM.44.2.595-597.2006 Mangili, 2005, Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia, Clin Infect Dis, 40, 1058, 10.1086/428616 Mariani, 2006, Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy, J Antimicrob Chemother, 58, 481, 10.1093/jac/dkl256 Cui, 2006, Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus, Antimicrob Agents Chemother, 50, 1079, 10.1128/AAC.50.3.1079-1082.2006 Rose, 2007, Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies, J Antimicrob Chemother, 60, 334, 10.1093/jac/dkm170 Stein, 2006, Tigecycline: a critical analysis, Clin Infect Dis, 43, 518, 10.1086/505494 Meagher, 2005, The pharmacokinetic and pharmacodynamic profile of tigecycline, Clin Infect Dis, 41, S333, 10.1086/431674 Paterson, 2006, Clinical experience with recently approved antibiotics, Curr Opin Pharmacol, 6, 486, 10.1016/j.coph.2006.07.001 Murphy, 2000, Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis, Antimicrob Agents Chemother, 44, 3022, 10.1128/AAC.44.11.3022-3027.2000 Lin, 2006, Dalbavancin: a new option for the treatment of gram-positive infections, Ann Pharmacother, 40, 449, 10.1345/aph.1G158 Raad, 2005, Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens, Clin Infect Dis, 40, 374, 10.1086/427283 Madrigal, 2005, Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus, Antimicrob Agents Chemother, 49, 3163, 10.1128/AAC.49.8.3163-3165.2005 Miró, 2007, Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus, Antimicrob Agents Chemother, 10.1128/AAC.01266-06 Kaatz, 1998, Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis, Antimicrob Agents Chemother, 42, 981, 10.1128/AAC.42.4.981 Bogdanovich, 2005, Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin, Antimicrob Agents Chemother, 49, 4210, 10.1128/AAC.49.10.4210-4219.2005 Chambers, 2005, Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus, Antimicrob Agents Chemother, 49, 884, 10.1128/AAC.49.3.884-888.2005